Stay Informed

Sign up for news & alerts

Already signed up?
Login here
What Can I Do?


Get Help
Need alcohol or drug help for yourself or someone else? GET HELP
Continuing Education
Free online courses for addiction counselors LEARN ONLINE
Resources
Resources
Find useful publications, online documents & more.


DrugScreening.org


 
FDA Calls for Suicide Warning on Antidepressants
March 23, 2004

Share Share Email
Email
Print
Print
SubscribeSubscribe
News Summary

Warning that some popular antidepressants may be linked to suicides, the Food and Drug Administration (FDA) is calling on drug makers to add a new warning to antidepressant labels, the Associated Press reported March 22.

Studies have not confirmed that the drugs actually lead to suicide; however, the FDA said stronger caution language should be added to labels for adults and children using antidepressants to treat depression.

The FDA also issued a public-health advisory for doctors, patients, families, and other caregivers to be aware of growing signs of depression or suicidal thoughts at the onset of antidepressant therapy or whenever the dosage is changed.

Among the drugs included in the warning are Prozac, Paxil, Zoloft, Effexor, Celexa, Remeron, Lexapro, Luvox, Serzone, and Wellbutrin.

COMMENTS ON THIS ARTICLE:

Your Turn! Post a public comment (read guidelines):

Name:

Comment:
(limit 200
words)
Enter this word
(help):		 Change

GUIDELINES: 
To keep this feature useful for all, please:

  1. Keep it clean, courteous, and on-topic. Comments are meant for thoughtful discussion of the article published above.

  2. Do not post promotional links to organizations, products or services, or personal requests for assistance (get help).

  3. Proof your comments carefully, use good spelling and punctuation, and don't use ALL CAPS. Comments are published immediately and cannot be edited.

Deceptive, slanderous and commercially-motivated posts are prohibited. We reserve the right to remove comments not conforming to these guidelines. (Report a comment).

Have questions or feedback? Contact us.